Annuncio pubblicitario
Italia markets close in 5 hours 44 minutes

  • FTSE MIB

    33.758,31
    +11,65 (+0,03%)
     

  • Dow Jones

    37.903,29
    +87,37 (+0,23%)
     

  • Nasdaq

    15.605,48
    -52,34 (-0,33%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    79,60
    +0,60 (+0,76%)
     

  • Bitcoin EUR

    53.939,68
    +382,81 (+0,71%)
     

  • CMC Crypto 200

    1.267,30
    -3,44 (-0,27%)
     

  • Oro

    2.309,30
    -1,70 (-0,07%)
     

  • EUR/USD

    1,0701
    -0,0017 (-0,16%)
     

  • S&P 500

    5.018,39
    -17,30 (-0,34%)
     

  • HANG SENG

    18.207,13
    +444,10 (+2,50%)
     

  • Euro Stoxx 50

    4.894,08
    -27,14 (-0,55%)
     

  • EUR/GBP

    0,8553
    -0,0000 (-0,00%)
     

  • EUR/CHF

    0,9762
    -0,0058 (-0,59%)
     

  • EUR/CAD

    1,4677
    -0,0029 (-0,20%)
     

Affimed to Present at the Cantor Global Healthcare Conference 2023

Affimed N.V.
·2 minuto per la lettura
Affimed N.V.
Affimed N.V.

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Financial Officer, Angus Smith, will participate in a fireside chat at the Cantor Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 1:15 p.m. Eastern Daylight Time / 19:15 Central European Time.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed’s management, please contact your Cantor representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

ANNUNCIO PUBBLICITARIO

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Mannheim, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102